Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,216 across all filing types
Latest filing 2016-03-01 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 29/02/2016, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements for a specific month, typical of a regulatory compliance report rather than a financial report or announcement of voting results. The document is comprehensive and contains substantive data on share capital changes, not merely an announcement or certification. Therefore, the best fitting category is 'Major Shareholding Notification' (MRQ) or 'Share Issue/Capital Change' (SHA). Since the document covers detailed movements in share capital including share options, warrants, convertibles, and other share-related changes, it aligns most closely with 'Share Issue/Capital Change' (SHA).
2016-03-01 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding the approval for drug registration and clinical trial from the China Food and Drug Administration. It is a short announcement (1518 characters) providing an update on product development and business progress. It does not contain financial data, detailed reports, or regulatory certifications. It is not an annual or interim report, earnings release, or any detailed financial or governance document. It is also not a voting result, capital change, or legal proceeding. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2016-02-24 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 100% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, SSY Group Limited, detailing changes in issued share capital and share buybacks. It includes specific data on shares repurchased and cancelled, dates, prices, and compliance confirmations with Listing Rules of the Hong Kong Stock Exchange. The content focuses on reporting share capital changes and share repurchase transactions, which aligns with announcements regarding share issues or capital changes. It is not a full financial report, audit, or earnings release, nor is it a meeting or voting result document. The detailed disclosure of share repurchases and issued shares fits the definition of a Share Issue/Capital Change announcement. The document length (6038 characters) and detailed tabular data confirm it is the actual disclosure, not just a brief announcement or report publication notice.
2016-02-18 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding the approval of a drug clinical trial. It is a brief update on product development and does not contain financial data, regulatory certifications, or detailed reports. The document length is short (1487 characters), and it is clearly an announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or certification. The best fitting category is a general Regulatory Filing (RNS) as it is a voluntary business update announcement that does not fit other specific categories.
2016-02-02 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/01/2016, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities movements rather than financial performance, management commentary, or regulatory certifications. It is a regulatory filing specific to share capital movements and securities, typical for compliance with stock exchange requirements. It is not an annual or interim report, earnings release, or management discussion. It is not a report publication announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement about share capital movements that does not fit into more specific categories like Share Issue/Capital Change (SHA) because it covers a broad range of securities movements and is a monthly return filing to the exchange.
2016-02-02 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding the approval for a drug clinical trial. It is an update on product development and does not contain financial data, regulatory certifications, or detailed report content. The document is short (1579 characters) and serves to inform shareholders and investors about business progress rather than presenting a formal report or financial results. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or regulatory filing. It is also not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category for voluntary business updates that do not fit other specific categories.
2016-02-01 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.